[Radioimmunotherapy of malignant diseases. Value and prospects].
Radioimmunotherapy is based on the use of radioactive agents (iodine 131, yttrium 90...), murine-derived monoclonal antibodies and specific tumour-related membrane antigens. This new treatment modality was applied in 800 patients with different types of malignant tumours which had not responded to traditional therapy. Among the haematologic tumours, the most promising results were obtained in B phenotype non-Hodgkin lymphoma. More modest results were obtained for solid tumours although good results were observed after intraperitoneal administration in patients with cancer of the ovary. The main side effects are acute reversible anaphylactic shock, haematologic toxicity and development of anti-murine human antibodies. Several methods are currently under study to increase irradiation dose delivered at the tumoural site since less than 1% of the injected radioactive dose is absorbed by tumoural cells. Several clinical studies are to be conducted in France, particularly for malignant non-Hodgkin lymphoma and cancer of the ovary.
Mahé
M A
MA
Service de Radiothérapie, Centre René Gauducheau, Saint-Herblain.
Chatal
J F
JF
D004067:Digestive System Neoplasms / Q000532:radiotherapy; D005260:Female; D006402:Hematologic Diseases / Q000532:radiotherapy; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D010051:Ovarian Neoplasms / Q000532:radiotherapy; D011379:Prognosis; D016499:Radioimmunotherapy / Q000639:trends
Radioimmunothérapie des affections malignes. Intérêt et perspectives.